X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PFIZER - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PFIZER AUROBINDO PHARMA/
PFIZER
 
P/E (TTM) x 17.7 23.8 74.5% View Chart
P/BV x 5.8 3.8 152.3% View Chart
Dividend Yield % 0.4 0.9 42.0%  

Financials

 AUROBINDO PHARMA   PFIZER
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
PFIZER
Mar-16
AUROBINDO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,5412,724 56.6%   
Low Rs5821,611 36.1%   
Sales per share (Unadj.) Rs237.5440.9 53.9%  
Earnings per share (Unadj.) Rs33.948.7 69.6%  
Cash flow per share (Unadj.) Rs40.675.8 53.6%  
Dividends per share (Unadj.) Rs2.5015.00 16.7%  
Dividend yield (eoy) %0.20.7 34.0%  
Book value per share (Unadj.) Rs120.6462.9 26.0%  
Shares outstanding (eoy) m585.1745.75 1,279.1%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.54.9 90.9%   
Avg P/E ratio x31.344.5 70.4%  
P/CF ratio (eoy) x26.228.6 91.4%  
Price / Book Value ratio x8.84.7 188.0%  
Dividend payout %7.430.8 24.0%   
Avg Mkt Cap Rs m621,04199,163 626.3%   
No. of employees `00013.32.9 460.0%   
Total wages/salary Rs m15,5082,758 562.4%   
Avg. sales/employee Rs Th10,457.66,981.7 149.8%   
Avg. wages/employee Rs Th1,167.1954.5 122.3%   
Avg. net profit/employee Rs Th1,491.6771.1 193.4%   
INCOME DATA
Net Sales Rs m138,96120,170 688.9%  
Other income Rs m1,663857 193.9%   
Total revenues Rs m140,62421,028 668.8%   
Gross profit Rs m32,0564,310 743.8%  
Depreciation Rs m3,9261,239 317.0%   
Interest Rs m2,5685 49,376.9%   
Profit before tax Rs m27,2253,923 693.9%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m7,4441,794 414.8%   
Profit after tax Rs m19,8202,228 889.7%  
Gross profit margin %23.121.4 108.0%  
Effective tax rate %27.345.7 59.8%   
Net profit margin %14.311.0 129.1%  
BALANCE SHEET DATA
Current assets Rs m100,01516,299 613.6%   
Current liabilities Rs m74,7597,594 984.5%   
Net working cap to sales %18.243.2 42.1%  
Current ratio x1.32.1 62.3%  
Inventory Days Days10765 164.5%  
Debtors Days Days11026 425.5%  
Net fixed assets Rs m52,3508,622 607.2%   
Share capital Rs m585458 127.9%   
"Free" reserves Rs m67,70720,722 326.7%   
Net worth Rs m70,56721,180 333.2%   
Long term debt Rs m8,47225 33,888.0%   
Total assets Rs m156,99429,137 538.8%  
Interest coverage x11.6755.5 1.5%   
Debt to equity ratio x0.10 10,171.1%  
Sales to assets ratio x0.90.7 127.9%   
Return on assets %14.37.7 186.1%  
Return on equity %28.110.5 267.0%  
Return on capital %37.719.0 198.7%  
Exports to sales %51.00.1 85,791.9%   
Imports to sales %18.817.5 107.8%   
Exports (fob) Rs m70,92712 591,056.7%   
Imports (cif) Rs m26,1933,526 742.9%   
Fx inflow Rs m71,01552 137,492.9%   
Fx outflow Rs m28,799140 20,573.8%   
Net fx Rs m42,216-88 -47,793.4%   
CASH FLOW
From Operations Rs m17,5963,436 512.1%  
From Investments Rs m-13,801-6,991 197.4%  
From Financial Activity Rs m-198-619 32.0%  
Net Cashflow Rs m3,597-4,174 -86.2%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 4.9 565.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.7 43.0%  
Shareholders   69,601 85,207 81.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS